myCOPD for self-management of chronic obstructive pulmonary disease (MIB214)
NICE has developed a medtech innovation briefing (MIB) on myCOPD for self-management of chronic obstructive pulmonary disease
Search results
1380 results
-
-
Laxatives (KTT1)
The key therapeutic topic laxatives has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
First-choice antidepressant use in adults with depression or generalised anxiety disorder (KTT8)
The key therapeutic topic first-choice antidepressant use in adults with depression or generalised anxiety disorder has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Renin-angiotensin system drugs: dual therapy (KTT2)
The key therapeutic topic renin-angiotensin system drugs: dual therapy has been retired from the 2017 update of medicines optimisation: key therapeutic topics. The version published in 2016 is available here for information but it has not been updated since February 2016. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Minocycline (KTT11)
The key therapeutic topic minocycline has been retired from the 2016 update of medicines optimisation: key therapeutic topics. The version published in 2015 is available here for information but it has not been updated since January 2015. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Psychotropic medicines in people with learning disabilities whose behaviour challenges (KTT19)
This document summarises the evidence base on psychotropic medicines in people with learning disabilities whose behaviour challenges . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Multimorbidity and polypharmacy (KTT18)
This document summarises the evidence base on multimorbidity and polypharmacy . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Acute kidney injury (AKI): use of medicines in people with or at increased risk of AKI (KTT17)
This document summarises the evidence base on the use of medicines in people with or at increased risk of acute kidney injury . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Anticoagulants, including direct-acting oral anticoagulants (DOACs) (KTT16)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on anticoagulants , including direct-acting oral anticoagulants (DOACs). It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Biosimilar medicines (KTT15)
The key therapeutic topic biosimilar medicines has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Wound care products (KTT14)
This document summarises the evidence base on wound care products . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Non-steroidal anti-inflammatory drugs (KTT13)
The key therapeutic topic non-steroidal anti-inflammatory drugs has been retired from the 2019 update of medicines optimisation: key therapeutic topics. The version published in 2018 is available here for information but it has not been updated since February 2018. Like all the other key therapeutic topics it is not formal NICE guidance .
-
Antipsychotics in people living with dementia (KTT7)
This document summarises the evidence base on antipsychotics in people living with dementia . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Hypnotics (KTT6)
This document summarises the evidence base on hypnotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Asthma: medicines safety priorities (KTT5)
This document summarises the evidence base on asthma: medicines safety priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Lipid-modifying drugs (KTT3)
This key therapeutic topic has been reincluded in the September 2019 update of medicines optimisation: key therapeutic topics. This document summarises the evidence base on lipid-modifying drugs. It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Type 2 diabetes mellitus: medicines optimisation priorities (KTT12)
This document summarises the evidence base on type 2 diabetes mellitus: medicines optimisation priorities . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Suicide prevention: optimising medicines and reducing access to medicines as a means of suicide (KTT24)
This document summarises the evidence base on suicide prevention: optimising medicines and reducing access to medicines as a means of suicide . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Shared decision making (KTT23)
This document summarises the evidence base on shared decision making . It is a key therapeutic topic that has been identified to support Medicines Optimisation. It is not formal NICE guidance .
-
Chemotherapy dose standardisation (KTT22)
This document summarises the evidence base on chemotherapy dose standardisation . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Medicines optimisation in chronic pain (KTT21)
This document summarises the evidence base on medicines optimisation in chronic pain . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Safer insulin prescribing (KTT20)
This document summarises the evidence base on safer insulin prescribing . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Antimicrobial stewardship: prescribing antibiotics (KTT9)
This document summarises the evidence base on antimicrobial stewardship: prescribing antibiotics . It is a key therapeutic topic that has been identified to support medicines optimisation. It is not formal NICE guidance .
-
Interstitial cystitis: dimethyl sulfoxide bladder instillation (ESUOM26)
Summary of the evidence on dimethyl sulfoxide bladder instillation for treating interstitial cystitis to inform local NHS planning and decision-making
-
Chronic pain: oral ketamine (ESUOM27)
Summary of the evidence on oral ketamine for treating chronic pain to inform local NHS planning and decision-making
-
Difficult-to-treat scabies: oral ivermectin (ESUOM29)
Summary of the evidence on oral ivermectin for treating difficult-to-treat scabies to inform local NHS planning and decision-making
-
Migraine prophylaxis: flunarizine (ESUOM33)
Summary of the evidence on flunarizine for treating migraine prophylaxis to inform local NHS planning and decision-making
-
Management of vomiting in children and young people with gastroenteritis: ondansetron (ESUOM34)
Summary of the evidence on ondansetron for the management of vomiting in children and young people with acute gastroenteritis...
-
Chronic anal fissure: 2% topical diltiazem hydrochloride (ESUOM3)
Summary of the evidence on 2% topical diltiazem hydrochloride for chronic anal fissure to inform local NHS planning and decision-making
-
Pouchitis: rifaximin (ESUOM30)
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
-
Type 2 diabetes: dulaglutide (ESNM59)
Summary of the evidence on dulaglutide for treating type 2 diabetes to inform local NHS planning and decision-making
-
Type 2 diabetes: insulin degludec/liraglutide (Xultophy) (ESNM60)
Summary of the evidence on insulin degludec/liraglutide (Xultophy) for treating type 2 diabetes to inform local NHS planning and decision-making
-
Orthostatic hypotension due to autonomic dysfunction: midodrine (ESNM61)
Summary of the evidence on midodrine for orthostatic hypotension due to autonomic dysfunction to inform local NHS planning and decision-making
-
Schizophrenia: aripiprazole prolonged-release suspension for injection (ESNM39)
Summary of the evidence on aripiprazole prolonged-release suspension for injection for schizophrenia to inform local NHS planning and decision-making
-
Premature ejaculation: dapoxetine (ESNM40)
Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making
-
Long-acting reversible contraception: levonorgestrel 13.5 mg intrauterine delivery system (ESNM41)
Summary of the evidence on the levonorgestrel intrauterine delivery system (long-acting reversible contraception) to inform local NHS planning...
-
Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)
Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making
-
Hyperphosphataemia in adults with chronic kidney disease on dialysis: sucroferric oxyhydroxide (ESNM51)
Summary of the evidence on sucroferric oxyhydroxide for treating hyperphosphataemia in adults with chronic kidney disease (CKD) on dialysis..
-
Chronic obstructive pulmonary disease: umeclidinium inhaler (Incruse) (ESNM52)
Summary of the evidence on umeclidinium inhaler (Incruse) for chronic obstructive pulmonary disease to inform local NHS planning and decision-making
-
Asthma in adults: beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) (ESNM53)
Summary of the evidence on beclometasone/formoterol dry powder inhaler (Fostair NEXThaler) for treating asthma in adults..
-
Chronic obstructive pulmonary disease: olodaterol (ESNM54)
Summary of the evidence on olodaterol for treating chronic obstructive pulmonary disease (COPD) to inform local NHS planning and decision-making
-
Combined oral contraception: nomegestrol/estradiol (Zoely) (ESNM28)
Summary of the evidence on nomegestrol/estradiol (Zoely) for use as combined oral contraception to inform local NHS planning and decision-making
-
Asthma: fluticasone/formoterol (Flutiform) combination inhaler (ESNM3)
Summary of the evidence on fluticasone/formoterol (Flutiform) combination inhaler for treating asthma to inform local NHS planning and decision-making
-
Prostate cancer: triptorelin (Decapeptyl SR) (ESNM30)
Summary of the evidence on triptorelin (Decapeptyl SR) for treating prostate cancer to inform local NHS planning and decision-making
-
Systemic juvenile idiopathic arthritis: canakinumab (ESNM36)
Summary of the evidence on canakinumab for treating systemic juvenile idiopathic arthritis (JIA) to inform local NHS planning and decision-making
-
Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)
Summary of the evidence on zonisamide as adjunctive therapy for partial seizures in children and young people (aged 6–17 years) with epilepsy..
-
Induction of labour: misoprostol vaginal delivery system (ESNM38)
Summary of the evidence on the misoprostol vaginal delivery system for induction of labour to inform local NHS planning and decision-making
-
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
-
Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)
Summary of the evidence on carbamazepine for managing aggression, agitation and behavioural disturbances in people with dementia..
-
Digital ulcers: sildenafil (ESUOM42)
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making